【摘要】 目的 观察自体DC-CIK联合肝动脉栓塞（TACE）治疗中晚期原发性肝癌的临床疗效。方法 中晚期原发性肝癌患者78例,随机分为自体DC-CIK联合TACE治疗（治疗组）40例和TACE治疗（对照组）38例两组,对照组给予单纯肝动脉化疗栓塞,治疗组给予自体DC-CIK联合肝动脉化疗栓塞。比较两组临床疗效、细胞免疫学指标、不良反应和患者生活质量。结果 治疗组细胞免疫学指标CD₃⁺、CD₄⁺/CD₈⁺、CD₅₆⁺治疗后较治疗前有明显改善（P=0.0235,P=0.0439,P=0.0298）,CD₄⁺、CD₁₆⁺治疗后较治疗前差异无统计学意义。对照组CD₃⁺、CD₄⁺/CD₈⁺、CD₄⁺、CD₅₆⁺、CD₁₆⁺治疗后较治疗前差异均无统计学意义。生活质量,治疗组患者治疗后乏力、失眠、纳差较治疗前明显改善,对照组患者改善不明显;治疗组KPS评分提高72.5%,对照组提高50.0%,差异有统计学意义（P=0.041）。治疗组有效率（RR）36.84%,对照组20.00%,差异无统计学意义（P=0.098）。中位生存期治疗组14.8个月,对照组13.2个月,差异无统计学意义（P=0.0896）。治疗组3例患者输注DC-CIK细胞后出现畏冷、寒颤、发热、2例患者回输后出现乏力、四肢肌肉酸痛.给予对症治疗后症状缓解。结论 自体DC-CIK联合TACE治疗中晚期原发性肝癌安全可行,能提高患者的免疫功能、改善生活质量,提高疗效。更多还原

【Abstract】 Objective To evaluate the clinical efficacy of DC-CIK cells combined with TACE for the treatment of advanced hepatocellular carcinoma（HCC）.Methods Totally 78 patients with advanced HCC were randomly divided into treatment group（n=40） and control group（n=38）.The patients in control group received TACE while those in treatment group were given TACE combined with DC-CIK cell treatment.The clinical effects、immune function quality of life and side effects were observed.Results The levels of CD₃⁺、CD₄⁺/CD₈⁺、D₅₆⁺ in the treatment group increased,which showed statistical difference（P=0.0235,P=0.0439,P=0.0298）,while those of the control group had no statistical difference after treatment（P>0.05）.The fatigue、insomnia and anorexia were improved in the treatment group（P=0.015 P=0.042,P=0.025）compared with the control group.The RR of KPS was72.5%in the treatment group,and 50.0%in the control group（P=0.041）.The response rate（RR） was 36.84%in the treatment group,and20.00%in the control group（P=0.098）.The median survival time of treatment group and control group are 14.8 months and 13.2 months（P=0.0896）.3 patients in the treatment group got chill and fever,2 patients got feeble and muscular soreness after DC-CIK treatment,and could be alleviated after symptomatic treatment.Conclusion DC-CIK cells combined with TACE for patients with advanced HCC is safe and effective and it plays an important role in improving immune function and quality of life of HCC patients.更多还原